Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1694-1703

  Ivanov, Roman ^a   Aarts, Tineke ^a   Hol, Samantha ^a   Doornenbal, Angeline ^a   Hagenbeek, Anton ^a   Petersen, Eefke ^a   Ebeling, Saskia ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; EPITOPE; HY ANTIGEN; PEPTIDE DERIVATIVE; PHYTOHEMAGGLUTININ; PROTEIN S 4; RIBOSOME PROTEIN; T LYMPHOCYTE RECEPTOR; THREONYLISOLEUCYLARGINYLTYROSYLPROLYLASPARTYLPROLYLVALYLISOLEUCINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA LIBRARY; EMBRYO; EPSTEIN BARR VIRUS; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LYMPHOBLAST; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROVIRUS; WESTERN BLOTTING;

ANTIGENS, CD40; BLOTTING, WESTERN; CELL PROLIFERATION; DNA, COMPLEMENTARY; EPITOPES; FEMALE; GRAFT VS LEUKEMIA EFFECT; H-Y ANTIGEN; HEMATOLOGIC NEOPLASMS; HLA-B ANTIGENS; HUMANS; MALE; PROTEIN ISOFORMS; RIBOSOMAL PROTEINS; SEX FACTORS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 16344393868     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1772     Document Type: Article

References (40)

1. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 2003;40:59-71.
2. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-76.
3. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
4. Sureda A, Schmitz N. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Ann Hematol 2003;82:1-13.
5. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-8.
6. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-5.
7. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003;100:2742-7.
8. Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004;103:353-9.
9. Verdijk RM, Kloosterman A, Pool J, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. Blood 2004;103:1961-4.
10. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004;103:347-52.
11. Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-90.
12. Vogt MH, Goulmy E, Kloosterboer FM, et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 2000;96:3126-32.
13. Pierce RA, Field ED, den Haan JM, et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J Immunol 1999;163:6360-4.
14. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002;99:3027-32.
15. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol 2000;164:2807-14.
16. Onishi M, Kinoshita S, Morikawa Y, et al. Applications of retrovirus-mediated expression cloning. Exp Hematol 1996;24:324-9.
17. Chiari R, Hames G, Stroobant V, et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000;60:4855-63.
18. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500.
19. + CML progenitor cells. Br J Haematol 2003;121:721-9.
20. Watanabe M, Zinn AR, Page DC, Nishimoto T. Functional equivalence of human X- and Y-encoded isoforms of ribosomal protein S4 consistent with a role in Turner syndrome. Nat Genet 1993;4:268-71.
21. Kircher B, Stevanovic S, Urbanek M, et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002;117:935-9.
22. Zinn AR, Alagappan RK, Brown LG, Wool I, Page DC. Structure and function of ribosomal protein S4 genes on the human and mouse sex chromosomes. Mol Cell Biol 1994;14:2485-92.
23. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003;423:825-37.
24. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
25. Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 2001;61:5511-6.
26. Labarriere N, Diez E, Pandolfino MC, et al. Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. J Immunol 1997;158:1238-45.
27. Lethe B, van der BP, Brasseur F, Boon T. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte. Melanoma Res 1997;7 Suppl 2:S83-8.
28. Chen FW, Ioannou YA. Ribosomal proteins in cell proliferation and apoptosis. Int Rev Immunol 1999;18:429-48.
29. Barnard GF, Staniunas RJ, Mori M, et al. Gastric and hepatocellular carcinomas do not overexpress the same ribosomal protein messenger RNAs as colonic carcinoma. Cancer Res 1993;53:4048-52.
30. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
31. Tsukasaki K, Tanosaki S, DeVos S, et al. Identifying progression- associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer 2004;109:875-81.
32. + T-helper cells in H-Y-mismatched transplantation. Lancet 2003;362:610-5.
33. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
34. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
35. Hernandez J, Garcia-Pons F, Lone YC, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 2002;99:12275-80.
36. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675-81.
37. Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-23.
38. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Oxford: Oxford University Press; 1992.
39. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999;96:8639-44.
40. Nijmeijer BA, Willemze R, Falkenburg JH. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice. Blood 2002;100:654-60.